NCT02235727View on ClinicalTrials.gov

Safety and Tolerability of GBR 900 in a Single Ascending Dose Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Healthy
Interventions
DRUG

GBR 900

DRUG

Placebo

Trial Locations (1)

LS29LH

Covance Clinical Research Unit Ltd, Leeds

Sponsors
All Listed Sponsors
collaborator

Glenmark Pharmaceuticals S.A.

INDUSTRY

lead

Glenmark Pharmaceuticals Ltd. India

INDUSTRY

NCT02235727 - Safety and Tolerability of GBR 900 in a Single Ascending Dose Study in Healthy Subjects | Biotech Hunter | Biotech Hunter